This content is machine translated Tofacitinib for ulcerative colitis Study shows real-world evidence for efficacy and safety The prevalence of ulcerative colitis (CU) in Switzerland is 1/500. The JAK inhibitor tofacitinib has been an arrow in the treatment quiver since 2019. In the phase 3 OCTAVE study,…
View Post 10 min This content is machine translated Chronic inflammatory bowel disease (CED) Modern “State-of-the-Art” Pharmacotherapy – an Update Modern approaches to the treatment of inflammatory bowel disease (IBD) are based on the motto “treat-to-target”, whereby in addition to symptom relief and induction of disease remission, the aim nowadays… CME-Test
View Post 6 min This content is machine translated RA therapy Let’s talk about JAKs The treatment of rheumatoid arthritis (RA) has made great progress over the past 20 years. This relates both to the range of drugs available and to developments in terms of…
View Post 3 min This content is machine translated Chronic inflammatory bowel disease (CED) Calprotectin as a therapy-relevant inflammatory marker Empirical findings show that calprotectin is the most important laboratory parameter for diagnosis as well as for monitoring the disease and therapy adjustments during its course. The treatment goal of…
